Fig. 6.

Metformin or rosiglitazone treatment prevents CAP-induced changes in circulating and bone marrow EPCs. Representative flow cytometry plots (i) and quantification (ii) of circulating (B) and bone marrow (C) Flk-1⁺/Sca-1⁺ cells in mice treated with water, metformin (Met), or rosiglitazone (Rosi) exposed for 9 days to air or CAP according to the indicated experimental protocol (A). EPCs were quantified as Sca-1⁺/Flk-1⁺ cells per 200 μl blood or per bone marrow mononuclear cells (BMMNC), and resulting numbers were normalized to the Sca-1⁺/Flk-1⁺ cells per 200 μl blood or per BMMNC in air-exposed mice treated either with water, metformin, or rosiglitazone. Data are means ± SE in % of air controls (*P < 0.05 air vs. CAP, n = 5).